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Network Embeddedness and New Product Development in the Biopharmaceutical Industry: 
The Moderating Role of Open Innovation Flow 
ABSTRACT 
This paper explores the role of centrality and structural holes positions on the likelihood to develop 
new products and the moderating role of the open innovation flow, a measure of the net knowledge 
flow crossing the firm‟s boundaries, on the aforementioned relation. We argue that network 
positions provide the information content to the firm, whilst open innovation flow describes how 
the firm uses such content, thus the combination of these two concepts has a significant impact on 
new product development. We test the theoretical framework on a large sample of 544 public 
companies and data from 1758 agreements among 1890 bio-pharmaceutical firms through the 
period 2006-2010. Our results show that being centrally located in the network positively affects the 
new product development process, while having a structural holes position has no effect on the 
aforementioned performance. However, the interaction of the two network positions with the open 
innovation flow has a positive impact on the likelihood to develop new products. 
Keywords: Inter-firm networks; Open Innovation; New Product Development 
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1. Introduction
Social Capital (SC) scholars highlight how structural network embeddedness influences the ability 
of the firm to develop innovations such as patents (Ahuja, 2000; Schilling and Phelps, 2007; Phelps, 
2010), significant improved products/services (Pèrez-Luño et al., 2011) and new product awards 
(Soh, 2003). Open Innovation (OI) scholars (Chesbrough, 2003) evidence how the incoming flow 
of knowledge provided through inbound OI practices (West and Bogers, 2013), such as in-
licensing, acquisition of R&D services and technologies, influences the firm‟s innovation 
performance such as patent development (Sampson, 2007), patent citations (Li and Tang, 2010) and 
new product development (Un et al., 2010). 
By analyzing the aforementioned contributes two interesting issues emerge. First, while OI 
scholars enhance our understanding of how openness improves new product development, to the 
best of our knowledge, SC literature has not examined specifically whether and how structural 
network embeddedness, i.e. the firm‟s network position, is able to improve the ability of the firm to 
develop new products. This omission is glaring, especially in the bio-pharmaceutical industry, 
where developing new products allows achieving monopoly rents for several years ahead. 
Second, a more relevant issue concerns the relation between the information asset provided by 
the network position and the use of such resources provided by the direction of the knowledge flow 
that the firm builds through OI practices. Indeed, while SC scholars point out the information 
dimension of network embeddedness by evidencing how information volume, diversity and 
richness, provided by different network positions, can enhance firm‟s performance, they fall short 
on tackling the potential benefits springing out from the actual use of such information in term of 
knowledge flow creation or dissipation (Koka and Prescott, 2002; 2008). On the other hand, OI 
scholars evidence the effect of an inflow of knowledge, provided by inbound practices, on 
innovation performance, however they ignore the role of firm‟s structural position as a source of 
information asset, enhancing the developing of the knowledge flow. Thus, the second contribute of 
this research is understanding how the direction of the knowledge flow across the organizational 
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 3 
boundaries provided by OI practices is able to enhance (or deteriorate) the positive effect that some 
network positions have on innovation performance. The importance of such contributes to the 
literature is recently highlighted by an editorial of a special issue on OI research where the authors 
affirm: “While research on strategic alliances has profited greatly from a network perspective, the 
link between open innovation and social capital is underdeveloped” (West et al., 2014: 809). 
In order to accomplish these aims, we define a measure of the net knowledge flow crossing the 
firm boundaries. We define open innovation flow as the attitude of a firm of balancing inflow of 
knowledge and outflow of knowledge through the prevalence of inbound and outbound practices; it 
is positive when inflow of knowledge is greater than outflow of knowledge and vice versa. Thus, 
the open innovation flow provides insights on how the firm uses the information content provided 
by its network position to enhance (or deteriorate) its capacity to develop new products. We build a 
theoretical framework and we test it within the bio-pharmaceutical context. We gather data on a 
network of inter-firm relations among bio-pharmaceutical firms through 2006 to 2010 using 
information from the BioWorld database. We construct the network characteristics by collecting a 
total amount of 1758 agreements among 1890 bio-pharmaceutical firms in the period 2006-2010. 
We collect data on patents, new products and firm attributes for a sample of 544 public companies 
belonging to the aforementioned network using multiple sources of other data.  
Our results show that, although structural embeddedness positions (centrality and structural 
holes) have a direct positive influence in the process of new product development, the effect is 
significantly amplified when a net positive knowledge flow is involved.  
The paper is organized as it follows. In section two, we develop the theoretical framework. Then, 
we describe the development of the dataset and explain the estimation models. Next, the empirical 
findings are presented. Finally, the paper concludes with a discussion of the theoretical and 
managerial implications of the study, some limitations of the research and suggestions for future 
research directions.  
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2. Conceptual development and hypotheses  
2.1. Structural network embeddedness and new product development  
As structural network embeddedness (Granovetter, 1992; Moran, 2005) we mean the “impersonal 
configuration of linkage between network actors” (Nahapiet and Ghoshal, 1998: 244) such as the 
presence or absence of ties, connectivity, centrality and hierarchy. SC scholars associate structural 
embeddedness with the extent of information a firm can obtain from its network of relations (Koka 
and Prescott, 2002; 2008). According to this view, structural embeddedness is analyzed along two 
network features. The first is centrality (Borgatti et al., 2002; Koka and Prescott, 2008); having a 
central network position provides the ego firm with information volume, i.e. a dimension 
emphasizing the quantity of information that a firm can access and acquire through its position in 
the network of inter-firm ties (Koka and Prescott, 2002).  
The second feature - structural holes - highlights the brokerage opportunities created by an 
open social structure (Burt, 1992). Structural holes are open and not densely tied network structures 
that provide the ego firm with entrepreneurial opportunities, i.e. the possibility to act as bridges 
between the different parts of the network (Koka and Prescott, 2008). Thus, by occupying a 
structural holes position a firm access to information diversity, i.e. the variety and to a somewhat 
lesser extent quantity of information that a firm can access through its relationships (Koka and 
Prescott, 2002). 
From the seminal work of Uzzi (1996), several scholars have tried to understand how structural 
network embeddedness influences organization‟s performance. Through an in-depth review of SC 
empirical studies, we examine scientific papers that have empirically investigated the role of the 
network embeddedness in explaining innovation and organizational performance. Table 1 
summarizes the results of the literature review. From the literature analysis, we found several 
scholars that evaluate the impact of network embeddedness on economic-financial performance of 
the firm (Koka and Prescott, 2002; Bae and Gargiulo, 2004; Zaheer and Bell, 2005; Maurer and 
Ebers, 2006; Shipilov, 2006; Acquaah, 2007; Goerzen, 2007; Shipilov and Li, 2008; Wu, 2008; 
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Malik, 2012) and some other scholars dealing with innovation performance (Ahujia, 2000; Soh, 
2003; Salman and Saives, 2005; Shilling and Phelps, 2007; Gilsing et al., 2008; Padula, 2008; 
Pieters et al. 2009; Vanhaverbeke et al., 2009; Phelps, 2010; Pèrez-Luño et al., 2011; Karamanos, 
2012; Vanhaverbeke et al., 2012). Specifically, Ahuja (2000) finds a positive effect of direct and 
indirect centrality of the firm on patent prolificacy, while structure hole positions seem to have a 
negative effect on the same performance. Soh (2003) evidences how a company improves the 
number of awards obtained for its products when it increases the number of repeated partners and 
centrality position relative to others. Salman and Saives (2005) find that by occupying a central 
position in a network of indirect ties, a firm is more likely to increase innovation performance 
(patent count). Schilling and Phelps (2007) empirically find that firms embedded in alliance 
networks, that exhibit both high clustering and high reach centrality, have greater patent 
performance. Gilsing et al.‟s (2008) findings clearly indicate that the number of explorative patents 
depends on other two dimensions of embeddedness, namely technological distance and network 
density. The study of Padula (2008) suggests that the development of a dual alliance network 
structure, made up of both cohesive and sparse relationships, provides higher rates of innovation 
performance (count of patents) than those from either pattern alone. Vanhaverbeke et al. (2009) find 
that firms can boost both explorative and exploitative patent count by shaping the degree of 
redundancy and density in their local alliance. Phelps (2010) evidences how the technological 
diversity of a firm‟s alliance partners increases its exploratory innovation (patent citations) and that 
network density among partners strengthens the influence of diversity. Karamanos (2012) 
empirically investigates how the interaction between a firm‟s alliance portfolio structure and the 
industry alliance network structure may be affecting the exploratory innovation outcome of network 
participating firms in the biotechnology industry. Finally, Vanhaverbeke et al. (2012) explain how 
direct ties have an inverted U-shaped effect on both core and noncore technology and, moreover, 
indirect ties play a positive role in noncore technology development. 
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Table 1. Literature review on SC and firm performance  
 
All the aforementioned SC studies basically focus their researches on patents as measure of 
innovation performance. However, new product development is a quite common measure of firm’s 
Authors Performance measures Operationalization 
Acquaah, 2007 Organizational performance Sales and revenues, Net Income, Return on 
Assets, Return on Sales, Growth in 
productivity 
Ahuja, 2000 Innovation output Number of successful patent applications 
Bae and Gargiulo, 2004 Organizational profitability Return on Investment, Return on Asset 
Gilsing et al., 2008 Explorative innovation performance  Number of patents 
Goerzen, 2007 Economic performance Operating return on sale, Return on Asset, 
Operating return on capital 
Karamanos, 2012 Innovation performance Number of patents 
Koka and Prescott, 2002 Firm performance Sales per employees 
Pèrez-Luño et al., 2011 Radical innovation Five-item scale regarding new or 
significant improved products/services 
Malik, 2012 Firm performance Return on Revenue 
Maurer and Ebers, 2006 Firm performance Revenue and employment growth, 
Patenting rate 
Molina-Morales et al., 2010 Innovation performance Innovation in processes and products 
Padula, 2008 Rates of innovation Number of successful patent applications 
Phelps, 2010 Degree of exploratory innovation Number of patent citations 
Pieters et al. 2009 Innovative performance Weighted patent counts 
Salman and Saives, 2005 Innovation performance Number of patents 
Shilling and Phelps, 2007 Knowledge creation  Number of successful patent applications 
Shipilov and Li, 2008 Firm’s market performance Revenue-generation abilities 
Shipilov, 2006 Firm performance Market Share 
Soh, 2003 New product performance Number of new product awards. 
Vanhaverbeke et al., 2009 Exploitative/explorative technology innovation Weighted patent counts 
Vanhaverbeke et al., 2012 Core/Non core technology Number of patent citations 
Wu, 2008 Firm competitiveness  Three items scale regarding firm’s 
competitors, products/services quality, 
reaction to market demand. 
Zaheer and Bell, 2005 Firm performance Market Share 
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innovation performance both in OI (Fey and Birkinshaw, 2005; Laursen and Salter, 2006; Vega-
Jurado et al., 2009; Un et al., 2010; Bianchi et al., 2011; Tomlinson and Fai, 2013; Bianchi et al., 
2014) and alliance literatures (Deeds and Hill, 1996; Rothaermel and Deeds, 2004; Kalaignanam et 
al., 2007). As shown in Table 1, none of the previous works adopt a new product development 
perspective as measure of innovation. There are two possible exceptions, i.e. Soh (2003) who 
however considers awards obtained by products, and Molina-Morales et al., (2010) who study, from 
a relational/cognitive perspective, the role played by the dimensions of social capital, measured as 
social interactions, trust, shared vision and involvement of local institutions, in process and product 
innovation. However, none of the two works consider the impact of network embeddedness 
measures on the count of new products developed. Thus, while it is well recognized in innovation 
management literature that new product development is necessary for firm survival and competitive 
advantage, especially in the high-tech industry, the SC literature disregards the effect of firm’s 
network positions on the likelihood to develop new products (Deeds and Hill, 1996; Rothaermel 
and Deeds, 2004; Kalaignanam et al., 2007; Vega-Jurado et al., 2009; Un et al., 2010; Bianchi et al., 
2011; Tomlinson and Fai, 2013). This omission is glaring, especially in the bio-pharmaceutical 
industry, where developing new products allows achieving monopoly rents for several years ahead. 
Thus, our analysis reveals a flaw in the SC literature: while OI and alliance literatures have 
considered the impact of OI practices and research collaborations on the new product development 
to measure the innovation performance, the SC literature has, until now, neglected this kind of 
performance. Thus, in order to fill this gap in literature, we discuss in the following how the 
aforementioned network positions, centrality and structural holes, impact on the likelihood to 
develop new products. 
 
2.1.1 Centrality 
Three kinds of benefits that arise from a central position have been associated to a positive impact 
on innovation outputs: knowledge gathering, knowledge accumulation, and scale (Ahuja, 2000). 
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First, firms centrally located in a network of inter-firm ties are able to gather large quantities of 
information about successes and failures and screen the most appropriate, and consequently, they 
are apprised to more information, and potentially have a greater capacity of monitoring their 
external environment and finding new information and knowledge (Ahuja, 2000). Second, Cohen 
and Levinthal (1990) show that the accumulation of knowledge enhances companies‟ abilities to 
recognize and assimilate new ideas, as well as their ability to convert this knowledge into further 
innovations. Following their absorptive capacity concept, companies that are more centrally located 
accumulate greater knowledge and information and, thus, will be in a better position to convert this 
knowledge into further innovations. Finally, being centrally positioned in a network allows scale 
economies in research that arise when larger projects generate significantly more knowledge than 
smaller projects (Ahuja, 2000). Of course, centrality also affects new product development 
capabilities of the firm. First of all, the firm can reduce the search costs for finding those external 
resources able to improve the product development process. For instance, by being centrally 
located, the firm can easily reach suppliers providing the best knowledge and capabilities for 
making the new product development process more successful (Ragatz et al., 2003; Mazzola and 
Perrone, 2013), or even they can select the most aligned patent or technology able to trigger or 
strengthen the new product development process (Geum et al., 2013), or finally getting in contact 
with potential customers whose commercial needs trigger new product development processes (He 
et al., 2014). Furthermore, a central position in the network allows accessing partners whose 
knowledge/technological base is not distant from the ego firm‟s, so that the firm could reduce the 
performance risk of unsuccessful technology acquisitions related with product development 
(Pisano, 1990; Billitteri et al., 2013). Finally, the learning capabilities provided by high information 
volume allow developing capability in dealing with inter-firm relationships that can be useful to 
improve collaborative product development processes (Kale and Singh, 2007). Under these 
circumstances, the above arguments lead to the first hypothesis. 
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Hypothesis 1: Being centrally located in a network of inter-firm relationships is positively related 
to the likelihood to develop new products. 
 
2.1.2 Structural Holes 
Structural holes are gaps in information flows between partners linked to the same ego network but 
not linked to each other (Zaheer and Bell, 2005). This structure implies access to mutually 
unconnected partners, and consequently, to many different information flows (Burt, 1992). The 
underlying mechanism posited by Burt (1992) is that firms bridging structural holes are able to 
access novel and diverse information from unconnected parts of the network.  
Traditional studies on networks suggest that structural holes are likely to be important to the 
firm‟s rate of innovation (Burt, 1992; Ahuja, 2000; Baum et al., 2000; Koput and Powell, 2003; 
Zaheer and Bell, 2005; Padula, 2008). For example, Baum et al., (2000) empirically investigate how 
Canadian companies in biotechnology industry that had heterogeneous mix of alliance partners 
enjoy faster revenue growth and a significant advantage in developing patents. Moreover, Koput 
and Powell (2003) show higher earnings and survival chances of those biotechnology firms that 
have more kinds of activities in alliances with different kinds of partners. Structural holes, 
providing connections with unusual ties operating in different industries, markets or technologies, 
promote diverse and non-redundant information that - by means of re-combination mechanisms - 
might help companies to develop new ideas and technologies for developing new products (Burt, 
1992; Ahuja, 2000; Rothaermael and Deeds, 2004; Gilsing and Nooteboom, 2005; Dittrich and 
Duysters, 2007; Gilsing et al., 2008; Koka and Prescott, 2008).  
A clear example of this is the IDEO case analyzed by Hargadon and Sutton (1997). Specifically, 
they describe processes by which a firm, IDEO, uses brainstorming to create new products. The 
firm‟s employees work for clients in diverse industries, so that in the brainstorming sessions, they 
use technological solutions from one industry to solve client issues in other industries where the 
solutions are rare or unknown. Thus, a firm bridging structural holes acts as the employees in the 
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Hargadon and Sutton (1997) example; it acts as a technology broker in different industries 
improving in this way the likelihood to develop new products. Galunic and Rodan (1998) build on 
the work of Hargadon and Sutton (1997) and found that a firm brokering several industries with its 
inter-firm relationships is able to broker the knowledge derived from the multiple industries to 
create new business concepts. They noted that when bridging structural holes, existing ideas and 
already developed technologies from a partner might appear new to the other, and vice versa, 
resulting in potentially new products or services. Zaheer and Bell (2005) found a positive 
relationship between structural holes and the extent to which companies improve their market share. 
Actors who bridge structural holes are able to developing new understandings, especially regarding 
emerging threats and opportunities, and efficiently and quickly learning about novel responses to 
industry trends in a manner that is not possible to those who do not bridge such holes (Zaheer and 
Bell, 2005). They posit that network position, as access to structural holes, exerts a multiplicity of 
positive influences on firm‟s performance, including enhanced efficiency, better access to 
information or knowledge, and better identification of and responses to threats and opportunities.  
Hence, according to the above reasoning we formulate the second hypothesis of the study. 
Hypothesis 2: Having a bridging structural holes position in a network of inter-firm relationships is 
positively related to the likelihood to develop new products. 
 
2.2 Structural embeddedness and new product development: the moderating role of the open 
innovation flow  
OI scholars focus on measuring how much the firm is open (Chiaroni et al., 2010; Dahlander and 
Gann, 2010), how and why the firm commercializes external sources of innovations (West and 
Borges, 2013), and how differentiated (breadth) or intensively exploited (depth) are the external 
search channels of the firm (Laursen and Salter, 2006). However, they have not taken into account, 
so far, the net flow of knowledge crossing the firm‟s boundaries. Thus, we define open innovation 
flow (OI_Flow) as the attitude of a firm of balancing inflow of knowledge coming from the use of 
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inbound practices and outflow of knowledge deriving from the application of outbound practices 
through the prevalence of inbound and outbound practices. In the case, where the firm is involved 
in more inbound practices than outbound ones, we say that the attitude of the firm of doing inbound 
of knowledge regards outbound of knowledge is prevalent and therefore the OI_Flow is positive. 
On the other hand, if the firm is engaged in more outbound practices than inbound ones, we say that 
the attitude of the firm of doing outbound of knowledge regards inbound of knowledge is prevalent 
and therefore the OI_Flow is negative. Finally, if the firm is involved in the same amount of 
inbound and outbound practices, we say that the attitude of the firm of doing inbound of knowledge 
regards outbound of knowledge it is equivalent and so the OI_Flow is neutral. Hence, our measure 
of OI_Flow accounts for how the firm uses the information content provided by its network 
position. SC scholars have acknowledged that having a central position provides the firm with a 
high volume of information, while having a structural holes position delivers high information 
diversity. In H1 and H2 we have hypothesized how being central or having a structural holes 
position in a network positively influences the likelihood to develop new products.  
However, a further important question concerns how the firm uses the information content 
provided by its network position and, in particular, whether a different use of such information in 
terms of in-flowing or out-flowing of knowledge strengths or weakens the relation between network 
positions and the likelihood to develop new products.  
We argue that if a firm mostly applies in-bound practices, i.e. the OI_Flow is positive, it means 
that the firm mostly uses the available information content provided by its central position to create 
an inflow of knowledge that strengths the development of new products (Fey and Birkinshaw, 2005; 
Vega-Jurado et al., 2009; Un et al., 2010; Tomlinson and Fai, 2013). For instance, having a central 
position in the network possible means that the firm is in contact with several potential suppliers of 
technologies, patents and services; this occurrence, by its own is able to improve the likelihood to 
develop new products as stated in H1; however, if the firm uses such information to build in-bound 
knowledge relationships with its possible suppliers, it uses its information content to involve such 
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suppliers in the new product development process and this further increases the probability to 
develop new products (Ragatz et al., 2003; He at al., 2014). Thus, if the firm associates a positive 
OI_Flow to its central position, its ability to develop new products is strengthen.  
On the contrary, if a firm mostly applies outbound practices, i.e. out-licensing, selling of R&D 
services and technologies, it uses its information content, provided by its central position, mostly to 
outflow knowledge to other firms; thus, if the firm is more focused on selling intermediate 
innovation products, like patents, technologies or services, then it is less likely to develop new final 
products on its own (Mazzola et al., 2012; Bianchi et al., 2014). Also, in this case, the high 
information volume provided by its central position allows the firm to easily find customers for 
selling its patents, technologies and R&D services. Consequently, the firm specializes itself in 
providing intermediate innovation products and fails to acquire those skills needed to develop final 
products. Thus, we expect that the more a firm creates an incoming OI_Flow the more it is able to 
use the volume of information provided by its central position in order to develop new products. On 
the other hand, the more a firm generates an out-going OI_Flow, the more the volume of 
information provided by its central position is used to sell intermediate innovations and this 
adversely affects the possibility to develop new final products.  
 
Figure 1. Anecdotal evidence of the interaction between centrality and OI_Flow 
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Figure 1 provides evidences concerning the previous considerations. It represents the 1-step 
network of 3 bio-pharmaceutical firms, i.e. Celgene Corp., PDL Biopharma Inc. and Xoma Ltd., 
during the period 2006-2010. The size of the node in the picture is proportional to the firm‟s 
eigenvector centrality, i.e. it accounts for direct and indirect centrality; thus, as the reader can notice 
they have the same eigenvector centrality. However, in the period 2006-2010, of its 8 ties, Celgene 
Corp. has performed 5 inbound practices with 5 different partners, while it has not performed any 
outbound practices. Thus, the net effect is a knowledge inflow (5-0>0), i.e. a positive OI_Flow. 
Celgene Corp. has developed two new products in the observed period. PDL Biopharma Inc., has 
performed 4 inbound and 4 outbound practices, thus it has a neutral OI_Flow (4-4=0) and it has not 
developed any product in the same period. Finally, Xoma Ltd. has performed 3 outbound practices 
and only 1 inbound practice in the period 2006-2010, thus it has an outflow of knowledge (1-3<0), 
i.e. a negative OI_Flow. It has not developed any product in the period. Hence, according to the 
above reasoning and the anecdotal evidences shown above, we formulate the third hypothesis of the 
model. 
Hypothesis 3: Open innovation flow moderates the relation between centrality and new product 
development; in particular, a positive open innovation flow, i.e. an inflow of knowledge, further 
increases the likelihood to develop new products.  
 
The positive effect of having a structural holes position in a network derives from the possibility to 
bridge diverse information that can allow the firm to find new applications for its technology, or 
new markets, or new business opportunities (Gilsing and Nooteboom, 2005; Dittrich and Duysters, 
2007). However, in order to exploit such information for the new product development process, the 
firm has to acquire technologies, patents or services, related with these information, that allow it to 
effectively develop new products. This consideration is quite similar to the new product 
development process proposed by Hargadon and Sutton (1997) for the IDEO‟s case study. Indeed, 
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the two scholars identify a process of new product development through the combination of 
different ideas brought by the brokering position of IDEO. The first step in this process is the 
definition of a structural holes position of the firm, and the second step is the acquisition of the 
knowledge that we identify with an incoming flow of knowledge, i.e. a positive OI_Flow.  
This is especially true in high-tech industries, such as the bio-pharmaceutical one. Let us 
consider for instance a common case in the bio-pharmaceutical market. Company “A” is a bio-
pharmaceutical firm possessing a technology platform that is already being used to develop 
products in a given therapeutic area. “A” could potentially get in contact with company “B”, who 
has developed and patented a new gene that can be modified through the “A” „s technological 
platform to develop a new drug. However, in order to develop the product, “A” needs to perform 
proper tests in the new therapeutic area and it does not possess the skill to do it. So, it could get in 
contact with the company “C” to acquire proper trial services. Thus, “A” could act as a bridge 
between “B” and “C” and getting the idea to use the gene from B to develop a new product in the 
therapeutic area of “C”. But, is having such information, provided by its structural holes position, 
enough to develop the new product? Of course not. In order to develop products “A” has to perform 
an inbound relation with its partners: it needs to buy the gene from “B” and trial services from “C”. 
Thus, just having the information provided by a structural holes position could be not enough to 
develop new products; the structural holes position has to be associated with an incoming 
knowledge flow (Figure 2a). What happens if “A” does not bridge the structural hole between “B” 
and “C” as in Figure 2b? In this case “A” loses the exclusivity of the information, so the possibility 
to exploit the information for its own purposes decreases. Indeed, “B” being in contact with “C”, 
could grow the idea to develop a new product for the therapeutic area of “C” on its own, or by 
acquiring technology services directly from “A”.  
Also in this case we can provide evidences shown in Figure 3. Millenium Pharmaceutical Inc. 
and Monogram Bioscience Inc. have the same constraint measure equal to 0.167, while Sequenom 
being constrained in a closed loop (clique) has a higher measure of constraint equal to 0.175. Thus, 
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Millenium and Monogram receive more exclusive information than Sequenom, i.e. they act as 
structural holes more than Sequenom. Of its 6 ties, Millennium Pharmaceutical has performed 4 
inbound practices and 1 outbound thorough 2006-2010. So, it has positive OI_Flow (4-1>0) and it 
has developed 3 products in the period. Monogram Bioscience Inc. has performed 4 outbound and 2 
inbound practices in the period 2006-2010, thus it has negative OI_Flow (2-4<0) and has not 
developed any product in the same period. Finally, Sequenom Inc. has performed 4 inbound and 1 
outbound practices in the period 2006-2012, and, even if its OI_Flow is positive (4-1>0), being 
more constrained, it has not developed any product in the period 2010-2012.  
 
 
 
 
 
 
 
a) Structural holes with incoming OI_Flow b) No structural holes 
Figure 2. Structural holes and OI_Flow 
 
 
Figure 3. Anecdotal evidence of the interaction between structural holes and OI_Flow 
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Hence, according with the above discussions and anecdotal evidences, we formulate the fourth 
hypothesis of the model. 
Hypothesis 4: Open innovation flow moderates the relation between structural holes position and 
new product development; in particular, a positive open innovation flow, i.e. an inflow of 
knowledge, further increases the likelihood to develop new products.  
 
3. Research method 
3.1 Sample and Data 
Since the mid 1970s the bio-pharmaceutical industry has been characterized by an increasing 
recourse to inter-firm agreements between big pharmaceutical firms and small new biotechnology 
firms. The basic explanation for the increasing number of inter-firm relationships in the industry is 
related to the extent of strong asset complementarities between the two types of firms (Billitteri et 
al., 2013). For these reasons, and because it is characterized by a high level of innovation openness, 
we chose the bio-pharmaceutical industry as the research setting of this study.  
We collect data on inter-firm collaborations between bio-pharmaceutical companies in the years 
2006-2010 through the BioWorld database, an online information service providing daily news and 
analysis, company coverage, patent reports, and other biotechnology information. The full dataset, 
in the observed period, includes 1758 agreements among 1890 firms that, accordingly with OI 
literature, are categorized into inbound, outbound and coupled practices (Chesbrough, 2003). By 
inbound practices we mean any agreement concerning in-licensing, acquisition of services, 
acquisition of technologies and assets, partial and full acquisitions. By outbound practices we mean 
any agreement concerning out-licensing, selling of services, selling of technologies, assets and 
divesting. By coupled practices we mean any agreement in which the firm co-makes something 
with a partner (co-developing, co-manufacturing, co-distribute), i.e. an agreement in which is not 
possible to identify a clear direction of the knowledge flow and the OI_Flow is indeed neutral. We 
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use the full dataset to find out the OI practices and the structural embeddedness network data of 
each firm. Then, from this dataset, we select all the public companies in it, specifically 544 firms, to 
ensure the availability and reliability of firm-attribute data. Thus, by selecting all the public firms in 
the dataset, no selection bias is present in our sample. We collect data about new products, 
patenting, and firm-attributes of this sample. We retrieve data on new product development from 
the “Biotech Products” section of BioWorld database. The patenting data are retrieved from the US 
Patents Office database. Finally, we collect firm-attribute data from the companies‟ annual reports.  
 
3.2 Measures 
3.2.1 Dependent variables 
In the innovation management literature, we find a long history of conflict within the theme of 
measuring firms’ innovation performance. Scholars have employed several kinds of measures to 
capture firms’ innovative performance, such as R&D inputs, patent counts, patent citations, counts 
of new product introductions, or more specific survey-based measurements (Ahuja, 2000; Soh, 
2003; Bae and Gargiulo, 2004). In literature, the two most applied measured are patents (counts, 
citations and so on) and the number of products developed. We acknowledge that substantial 
differences exist in measuring innovation performance as patents or new products. These two 
measures indicate the achievement in the innovation path from conception and development of new 
ideas (patenting) up to the introduction of an invention into the market (new product development). 
Specifically, we focus on product perspective disregarding the patent point of view, and the 
comparison between the two innovation measures, due to the following rationales. Firstly, SC 
literature has specifically investigated the effect of network positions on patent propensity of a firm, 
not considering if network positions differently impact others kinds of innovation performance, 
such as new product development. Secondly, considering the industrial context under analysis, a 
consistent part of the literature analysing innovation performance in the bio-pharmaceutical industry 
focuses on new products as a direct measure of how well a ﬁrm performs within a new 
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technological paradigm. As already highlighted by Pisano (1990), developing new products is 
increasingly a focal point of competition and often requires the development and successful 
implementation of novel process technologies. Especially in the bio-pharmaceutical industry, by 
introducing a new drug in the market the firm gains a temporary monopoly profits for 10-15 years 
ensuring in this way cash, market share and getting reputation among physicians, customers and 
government agencies (Lieberman and Montgomery, 1988). Thus, several scholars within this 
industry assume the number of new products developed as a measure of innovation performance 
(Rothaermel, 2001; Rothaermel and Deeds, 2004; Kalaignanam et al.,  2007; Bianchi et al., 2011).  
Nevertheless, since developing new drugs is a long and costly process (DiMasi and Grabowski, 
2007), in order to measure the ability of the firm to develop new bio-pharmaceutical products, we 
operationalize the dependent variable of this study in two ways: how the firm is prolific in 
developing many products during the period 2010-2012, NewBioProd_c, and whether the firm has 
developed at least one new bio-pharmaceutical product in the observed period, NewBioProd_d. 
Thus, NewBioProd_d is a binary variable that is one when the company introduces at least one new 
product in the period 2010-2012, zero otherwise; while, NewBioProd_c is a count variable obtained 
by summing all the products developed by the firm in that period.  
Because of bio-pharma companies may not have a new drug marketed every year, to assess 
different lag specifications between the investigation variables and the dependent one we adopt an 
approach quite applied in literature (Rothaermel and Deeds, 2004; Salman and Saives, 2005; 
Padula, 2008; Phelps, 2010; Vanhaverbeke et al., 2012); according to this approach, both the 
dependent variables are calculated considering the 3 years succeeding the 5 years bio-
pharmaceutical company agreements‟ observations, that is the period 2010-2012.  
 
3.2.2 Independent variables 
As the structural embeddedness network variables, we use two explanatory variables: Centrality 
and Structural Holes. To calculate these two network measures we first collect Bioworld data and 
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define an inter-firm collaborations‟ matrix, containing all the agreements established among the 
1890 bio-pharmaceutical firms throughout 2006 to 2010. Among the different network measures 
that have been utilized to capture the notion of centrality, we use the Eigenvector Centrality (Eigen) 
that accounts for both direct and indirect company ties. The most central companies are those linked 
to many firms, which are in turn linked to several other firms. We choose eigenvector centrality 
since it is a good measure of information volume (Koka and Prescott, 2002), that is what, in our 
perspective (see hypothesis 1), influences the new product development, and also because, in 
literature, it has been often related to innovation performance (Ahuja, 2000; Salman and Saives, 
2005; Padula, 2008). To evaluate eigenvector centrality and structural holes measures we use 
UCINET VI (Borgatti et al., 2002), a network analysis program that computes network variables by 
using dyadic data. Following prior literature, we measure Structural Holes (Str_holes) as one minus 
the firm‟s constraint score (in cases where constraint was non-zero) and zero for all other cases, 
because a score of zero in our network happens only when the firm is unconnected to others, so it 
has no access to structural holes. Constraint is the far most used measure for accounting of structure 
hole positions in literature (Ahuja, 2000; Zaheer and Bell, 2005; Shipilov, 2006; Shipilov and Li, 
2008). Furthermore, the measure has been associated to information diversity (Koka and Prescott, 
2002), which indeed is what we would like to capture. 
With regards to the OI measures the issue of how measuring OI is a hot topic among 
innovation scholars (Dahlander and Gann, 2010). This is also highlighted by the editors of the 
recently Research Policy special issue on Open Innovation (West et al., 2014) that define how 
measuring OI is one of key trends in OI research (Belderbos et al., 2014). OI scholars focus on 
measuring how much the firm is open (Chiaroni et al., 2010) and how differentiated (breadth) or 
intensively exploited (depth) are the external search channels of the firm (Laursen and Salter, 
2006). More recently several authors have assumed a “practice-based” perspective for measuring 
the degree of openness of a firm (Dahlander and Gann, 2010; Mazzola et al., 2012; Burcharth et al., 
2014; Dahlander and Piezunka, 2014; Mina et al., 2014). This measure consists on counting the 
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number of practices of inbound and/or outbound a firm adopts. By choosing this approach in here 
we are able to consider in one measure the multifaceted nature of the OI concept. However, since 
the concept of OI is both transactional and relational (Laursen and Salter, 2006), in order to decide 
which OI practices to consider in measuring the OI_Flow we follow the taxonomy proposed by 
Dahlander and Gann (2010). In particular, they define “sourcing” category as the inbound 
innovation-nonpecuniary option, whereas “acquiring” category is the inbound innovation-pecuniary 
choice. In addition, they define “revealing” category as the outbound innovation- nonpecuniary 
option, while “selling” category is the outbound innovation- pecuniary option. For the purpose of 
this research, we find appropriate to limit the discussion to the “pecuniary” side of OI, considering 
both inbound and outbound strategies. The acquiring category (inbound innovation-pecuniary) 
captures those OI activities in which a firm acquires input to innovation processes in exchange for 
market prices. The selling category (outbound innovation-pecuniary) captures those OI activities in 
which a firm commercializes internally already developed knowledge outside its boundaries in 
exchange for market prices. By focusing on those kinds of OI practices we assume a transactional 
perspective of the OI exchange that allows making inbound and outbound practices more 
comparable each other. Practically, to construct OI_Flow variable, we count how many times each 
company is involved, in the period 2006-2010, in the following inbound acquiring practices: in 
licensing, i.e. the purchasing of IP assets (Tsai, 2009); purchasing of services (including R&D and 
manufacturing) and purchasing of technologies and assets (Tsai, 2009; Chiaroni et al., 2010; Un et 
al., 2010); partial and full acquisitions of other firms (Vanhaverbeke et al., 2002). While as category 
of outbound selling we have considered those OI practices through which a firm can commercialize 
its inventions and technologies through selling or licensing out resources that are developed within 
the organizations (Bianchi et al., 2014). Specifically, we count how many times, in 2006-2010, each 
company is involved in the following outbound selling practices: out-licensing, i.e. the selling of 
firm‟s IP (Lichtenthaler, 2009); supply of scientific, technological, and manufacturing services 
(Tsai, 2009; Chiaroni et al., 2010); external technology commercialization, i.e. the numbers of 
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agreements for commercialization and distribution the firm engages in that period (Kutvonen, 
2011); divesting, i.e. the number of divisions, business unit and products lines the firm sells from 
2006 to 2010 (Lee and Madhavan, 2010). 
As already mentioned, with the OI_Flow we would like to measure the net knowledge flow 
crossing the firm boundaries; it is equal to +1 if the firm has realized in the period 2006-2010 more 
inbound practices than outbound ones; thus, +1 identifies an attitude of the firm to build a net 
incoming knowledge flow in the period. Conversely, OI_Flow is -1 in case the firm has more 
outbound practices than inbound ones, so that -1 identifies a net out-going knowledge flow. Finally, 
OI_Flow is 0 if the number of inbound practices is equal to the number of outbound practices in the 
period or if the company has realized only coupled practices throughout 2006-2010. Thus, 0 
identifies a neutral OI_Flow, either coming from an equal number of inbound and outbound 
practices or from coupled practices. Some necessary clarifications are needed about the measure of 
the open innovation flow we assume in here. Firstly, even if we compare OI practices that are 
transactional based (inbound acquiring and outbound selling), we do not assume a strictly 
compensation between inbound and outbound flows, thus we dichotomize the variable. Indeed, by 
measuring the OI_Flow as the difference between the number of inbound and outbound practices it 
would have meant to assume a strict compensation among practices; vice versa, the dichotomized 
variable simply indicates that a firm playing more inbound than outbound it is more likely to have 
an inflow of knowledge. Secondly, in our measure, coupled practices, i.e. alliances, have no impact 
on OI_Flow, since, as said, they are neutral; however, this does not mean that alliances have no 
effect on innovation performance of the firm, which, indeed, is a quite acknowledged result in 
alliance literature (Deeds and Hill, 1996; Rothaermel and Deeds, 2004). We would like to recall 
here that our hypotheses 3 and 4 are related to a moderator effect of the OI_Flow on the direct 
relationship between centrality/structure holes and new product development, thus no direct effect 
of the OI_Flow on performance is hypothesized in this study. Finally, our measure of OI_Flow 
relies on the same data we used to calculate eigenvector centrality and structure holes measures; 
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however, it is a diverse measure as the anecdotal examples clearly show and how the low 
correlation values reported in Table 2 confirms.  
 
3.2.3 Control variables 
Many other factors may influence the likelihood to develop new biotechnological products. One 
important control variable we include is Patent stock. Patent stock reflects the level of technological 
capital, absorptive capacity and R&D know-how of a company (Vanhaverbeke et al., 2009; Phelps, 
2010) and thus we may expect a positive relation of this variable on new product development. 
However, we can also expect a negative influence of the patent stock on the dependent variable, in 
case the firm specializes itself on developing and selling patents and, in this way, it neglects the 
development of new products (Phelps, 2010). We control for the number of patents a firm obtains in 
the thirty years up to 2010. Since R&D expenditures are a significant determinant of innovation 
outcomes (Bae and Gargiulo, 2004; Phelps, 2010), we introduce the second control variable, i.e. 
R&D Expenditures. We operationalize firm‟s R&D expenses as the natural logarithm of average 
R&D expenditures in the years 2006-2010. Moreover, we include the variable Pipeline as control. 
Indeed, products in the pipeline represent accumulated stocks of knowledge (Decarolis and Deeds, 
1999), and they could have a direct relationship to innovation outcome, even if in the 
biopharmaceutical industry products under development are often sold as intermediate innovation 
products. We count the number of products in the firm‟s pipeline up to 2010. We include an 
Industry dummy variable to indicate whether a company is a pure biotechnological or a bio-
pharmaceutical one (Vanhaverbeke et al., 2009). Indeed, the more a biotech firm is integrated 
downstream in the development of drugs, the higher the likelihood to develop new products 
(Billitteri et al., 2013). Finally, we include the Nationality of the firm as control (Ahuja, 2000); this 
is a dummy variable that is one if the company is US one, zero otherwise. Indeed, 341 out of 544 of 
the firms in our sample are American, a market that is more developed for biopharmaceutical 
products, thus we expect that being located in the US has a positive impact on the likelihood to 
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develop new products (Phelps, 2010; Vanhaverbeke et al., 2012). We had originally introduced also 
a control for the size of the firm measured as the natural logarithm of the average employees of 
each firm in the period 2006-2010 (Ahuja, 2000). However, this variable showed serious 
collinearity problems with the variable R&D Expenditures, so we decided to drop Size and to keep 
the R&D Expenditures because this last variable is more fitting the model. 
 
4. Results 
Table 2 provides the descriptive statistics and the correlations between all the variables. The 
correlation coefficients between the independent variables are quite low. Also, the VIF (variance 
inflation factor) value is below the critical level, indicating that the explanatory variables can 
simultaneously be included in the models (Stevens, 1992; Gujarati, 1995). It is interesting to notice 
how the correlations between Eigen, Str_holes and OI_Flow are respectively 0.00 and 0.04, 
evidencing how the network variables measure a completely different concept than OI_Flow, even 
if they are derived by the same dataset.  
 Mean SD Min Max (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) 
1. NewBioProd_d 0.11 0.31 0 1 1.00 
         
2. NewBioProd_c 0.18 0.71 0 11 0.71 1.00 
        
3. Patent stock 76.73 327.38 0 3359 0.16 0.40 1.00 
       
4. R&D Expenditures 2.69 1.78 0 9 0.33 0.33 0.43 1.00 
      
5. Pipeline 5.84 11.25 0 150 0.21 0.32 0.34 0.32 1.00 
     
6. Industry 0.61 0.498 0 1 0.10 0.01 0.03 0.08 0.03 1.00 
    
7. Nationality 0.37 0.48 0 1 -0.06 -0.07 -0.04 -0.08 0.09 -0.09 1.00 
   
8. Eigen 1.06 3.48 0 47.1 0.19 0.50 0.32 0.25 0.23 -0.14 -0.01 1.00 
  
9. Str_holes 0.35 0.34 0 1 0.12 0.16 0.18 0.23 0.12 -0.1 0.00 0.35 1.00 
 
10. OI_Flow 0.03 0.83 -1 1 0.07 0.11 0.09 0.13 0.11 0.01 0.00 0.00 0.04 1.00 
Table 2. Descriptive statistics and correlation matrix  
 
4.1. Probit models 
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NewBioProd_d is a dichotomous variable, thus we use a “probit” model (Hoetker, 2007). The probit 
and logit regression models tend to produce very similar predictions and the choice between the 
logit and probit models is largely one of convenience and convention, since the substantive results 
are generally indistinguishable (Long, 1997).  
Table 3, models 1-4, provides an overview of the results of the probit model. Model 1 contains 
all the control variables. Model 2 evaluates the main effects of centrality and structural holes. Since 
the interaction term may be highly correlated with the first-order predictor variables from which it 
is derived, to create all the interaction items we mean-centered the first-order variables Eigen, 
Str_holes, OI_Flow to reduce the potential multicollinearity (Little et al., 2006). Furthermore, we 
sequentially and separately include the two interaction effects in Models 3 and 4 in order to track 
coefficients and significance levels (Dalal and Zickar, 2012). Indeed, by looking at the overall fit of 
each of the models, we observe that the introduction of structural embeddedness network measures 
in model 2 significantly improves the fit. Another significant improvement occurs in models 3 and 
4, with the introduction of the two interaction effects. 
As expected, R&D Expenditures has a positive and significant effect in all the models. The 
Patent stock coefficient is negative and significant in models 2, 3 and 4. This confirms that the more 
a bio-pharmaceutical firm is specialized in the upstream phase of the supply chain, the research 
phase, the more its business model is based on producing and selling patents and technological 
services instead of developing new products. The Industry coefficient is positive and significant in 
all the models; as expected, the more a company is downstream integrated in the pharmaceutical 
market, the higher is the likelihood to develop new products. Finally, Nationality and Pipeline do 
not achieve statistical significance.  
Model 2 introduces the Eigen and Str_holes as explanatory variables. According to H1, we 
expect a positive relation between centrality and new product development propensity. As shown in 
model 2, the coefficient of Eigen is significant and the sign is as predicted; this means that being 
centrally located in a network increases the likelihood to develop new biotech products.  
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According to H2, we hypothesize a positive relation between structural holes and new product 
development. As depicted in model 2 the coefficient for Str_holes is positive, as expected, but it is 
not significant.  
Model 3 introduces the pairwise interaction term between Eigen and OI_Flow in order to test 
H3; we expect a positive interaction effect between centrality and open innovation flow. As model 
3 shows, the interaction term (EigenXOI_Flow) is positive and significant, so, H3 is confirmed.  
Finally, Model 4 introduces the pairwise interaction term between Str_holes and OI_Flow in 
order to test H4; we predict a positive interaction effect between structural holes and open 
innovation flow. As shown in model 4, the interaction term (Str_holesXOI_Flow) is positive and 
significant, so also H4 is confirmed. 
As highlighted by Hoetker (2007), interaction terms in probit and logit models should be 
carefully interpreted. Indeed, in this case, the marginal effect of a change in both interacted 
variables is not equal to the marginal effect of changing just the interaction term as normally applies 
in linear models. More surprisingly, the sign may be different for different observations, thus the 
appraisal of the interaction term cannot only be determined from significance of the z-statistic 
reported in the regression output. In this case, besides the interpretation of the significance of the z-
statistic of the coefficient, a graphical presentation of the interaction term for the different 
observations is almost required (Hoetker, 2007). For this reason, we apply the STATA's inteff 
command (Norton et al., 2004) to our dataset in order to verify that the sign of the z-statistic of the 
coefficient of the interaction term is the same as that of the z-statistic of the observations. Results 
from the application of the command are reported in Figures 4 (a-d). As shown in Figure 4a and 4b, 
all the interaction effects of the observations, with the exception of 3, are positive, and all the z-
statistics of the single observation, except 3, are also positive. This confirms the probit results. Also 
the analysis of the z-statistic significance is quite good; indeed, looking at Figure 4b, when moving 
from a probability to develop a product close to zero, the z-statistics are above the red line 
delimiting the significance area; furthermore, the few negative z-statistics are all not significant. 
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Moving to the interaction effect between Str_holes and OI_Flow, by looking at Figures 4c and 4d 
the same considerations of above hold. 
 
 
 
Figure 4a. Interaction effects of EigenXOI_Flow Figure 4b. z-statistics of the interaction effects of 
EigenXOI_Flow 
  
Figure 4c. Interaction effects of Str_HolesXOI_Flow Figure 4d. z-statistics of the interaction effects of 
Str_HolesXOI_Flow 
 
4.2 Negative binomial models 
NewBioProd_c is a count variable that takes only non-negative integer values. Since the dependent 
variable indicates over-dispersion, as depicted in Table 2, (mean of 0.18 and S.D. of 0.71), a 
negative binomial estimation provides the better fit for count data than the more restrictive Poisson 
model. Table 3, models 5-8, provides an overview of the results of the negative binomial models. 
Also in this case, the likelihood ratio tests reported in Table 3 indicates that each model represents a 
significant improvement over the baseline model (Model 5).  
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Starting from the control variables, the results are the same of the logit model for the variables 
Patent Stock, R&D expenditures and Industry. Differently from the logit model, we find that the 
Nationality variable is negative and significant in all the models; meaning that US firms, as 
expected, develop more biotech products. Finally, the coefficient Pipeline is significant and positive 
in all the models; so, as expected, having a rich pipeline influences positively the number of 
products developed.  
In Model 6 the coefficient of Eigen is significant and the sign is as predicted; this result 
corroborated H1. Moreover, also in this case, Str_holes has a positive coefficient but is not 
significant. In models 7 and 8 the coefficients of the interaction terms EigenXOI_Flow and 
Str_holesXOI_Flow are both positive and significant as expected; so, also H3 and H4 receive, from 
the binomial model, a corroborated confirmation.  
 
5. Discussion and conclusions 
The results of the empirical analysis show a consistent support to our theoretical framework and 
contribute significantly to the literature on the issue.  
In hypothesis 1 we posit how having a central position in a network of inter-firm relationships 
has a positive impact on the likelihood to develop new products. The positive coefficient in all the 
models of Tables 3 of the eigenvector centrality (Eigen) confirms our intuition that accessing a high 
volume of information allows the firm to find more suitable supplier collaborations (Ragatz et al., 
2003; Tsai, 2009; He at al., 2014) and/or to locate intermediate innovation products (patents, 
technologies, services etc.) that better fit the product development projects of the firm (Geum et al., 
2013). Although this result is quite in line with other empirical works concerning other innovation 
performance (Ahuja, 2000; Soh, 2003), to the best of our knowledge, it is the first showing the 
positive influence of a central position on the effectiveness of the new product development 
process; thus, our results strengthen the importance of being central in a network of inter-firm ties 
to gain innovation performance.  
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In hypothesis 2 we predict a positive relation between structural holes position and the likelihood 
to develop new products. Although the sign of the coefficient in the models is positive, it never 
turns out significant. This finding reflects the dualistic debate in literature that offers different 
explanations for the role of structural holes. Following Burt (1992), several scholars have 
hypothesized a positive influence of structure holes on firm performance. Most of the empirical 
confirmations about this position are obtained for economic and financial performance (Zaheer and 
Bell, 2005; Shipilov, 2006; Shipilov and Li, 2008). However, according to Coleman (1988) 
searching through structural holes might lead to deteriorate the innovative propensity of a firm. 
Indeed, having a structural holes position exposes the firm to a higher volume of diverse 
information (Gnyawali and Madhavan, 2001); to recognize, assimilate, transform, and exploit these 
information for creating new products, a firm must put greater effort and resources (Cohen and 
Levinthal, 1990). The problem is that there is a limit to the absorptive capacity of a focal firm. 
Moreover, when knowledge components become more diverse, the lack of specialization and focus 
makes the recombination of this knowledge in new valuable ideas difficult, thus decreasing the 
innovation rate. Thus, when dealing with innovation performance, absorptive capacity problems 
become highly significant; indeed, Ahuja (2000) empirically finds a negative influence between 
structural holes and patent propensity of a company. On the other hand, Padula (2008) finds that a 
firm occupying a position that bridges network clusters is able to improve its patent propensity. The 
basic conclusion that emerges from the contrasting result between Ahuja’s (2000) and Padula’s 
(2008) studies is that whether structural holes are good, bad, or irrelevant is a function of the 
context under analysis. Thus, considering the nature of ties and the innovation performance 
measured, in our hypothesis we have predicted a positive effect of structural holes on new product 
development. Indeed, focusing on new product development point of view, in a network consisting 
of competitive linkages between firms belonging to the same industry, bio-pharmaceutical 
companies act as technology brokers (Hargadon and Sutton, 1997). This brokerage position 
increase the probability to develop new products due to the ability of the firm to collect different 
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information that can be useful in finding new applications of existing technologies, or new business 
opportunities for existing products. Our results show that, diversely from patents (Ahuja, 2000; 
Padula, 2008), having a structural holes position does not have any effect on new product 
development. So we might conclude that brokering different information, if from one hand has an 
effect (discordant) on patent propensity, it is not enough to improve the new product development 
rate of a company. Most important, as we are going to explain in the following, we found that in a 
network of competitors the structural holes position has a positive effect on developing new 
products due to the OI_Flow activation. Thus, only by associating an incoming flow with a 
structural holes position a firm can increase its propensity to develop new products. 
As concerns the interactions between structural network embeddedness and OI_Flow, the former 
provides information content to the firm, while the latter indicates whether such information content 
results in an entering knowledge flow (inbound) or an exiting one (outbound). In hypothesis 3 we 
hypothesize how an incoming flow of knowledge further increases the likelihood to develop new 
products, while an outgoing flow of knowledge decreases the likelihood to develop new products. 
The positive and significant sign of the interactions between Eigen and OI_Flow in model 3 (the 
logit model) and model 7 (the binomial model) confirms the prediction that when the OI_Flow is 
positive, the likelihood to develop a new product, as well as the number of new products developed, 
increases. In Figures 5a and 5c we plot, respectively, the predicted probability to develop a new 
product and the predicted number of products developed when the eigenvector centrality increases 
in two cases: OI_Flow = -1, +1. When high centrality is associated with an outgoing flow (OI_Flow 
= -1), the probability to develop new product is lower and slightly decreasing with the centrality. 
This confirms our intuition that the availability of a high volume of information and an attitude of 
the firm to perform outbound selling practices allows the firm to easily finding possible customers 
for selling its intermediate innovation products (patents, technologies or services). This focalizes 
the firm on selling intermediate innovation, reducing the likelihood to develop final products. On 
the contrary, when high centrality is associated with inbound acquiring practices, i.e. an incoming 
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knowledge flow (OI_Flow = +1), the predicted probabilities highly increase with the eigenvector 
centrality because, the firm uses the available information to acquire new knowledge and 
innovation assets that can be used to develop new products. 
In hypothesis 4 we predict a positive effect of the interaction between structural holes and open 
innovation flow. Again, the positive and significant sign of the interaction between Str_holes and 
OI_Flow both in models 4 and 8 confirms this prediction. Figures 5b and 5d plot, respectively, the 
predicted probability to develop a new product and the predicted number of products developed 
when Str_holes increases in two cases: OI_Flow = -1, +1. Also in this case, when structural holes 
positions are associated with outbound practices (OI_Flow = -1), the predicted probabilities 
decrease with the strengthening of the position of structural holes. On the other hand, when 
structural holes position is associated with an inbound flow (OI_Flow = +1), the probability to 
develop new product is higher and it increases with a stronger structural holes position. 
 
 
 
Figure 5a. Interaction EigenXOI_Flow - Predicted 
probability of developing a new product 
Figure 5b. Interaction Str_holesXOI_Flow - Predicted 
probability of developing a new product 
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Figure 5c. Interaction EigenXOI_Flow - Predicted 
number of new products developed  
Figure 5d. Interaction Str_holesXOI_Flow - Predicted 
probability of new products developed  
 
This result is quite interesting if considering the empirical results we get for the principal effect, i.e. 
structural holes position does not influence alone the probability to develop new products. Thus, 
only by associating an incoming flow with a structural holes position a firm increases the 
probability to develop new products. This result is quite in line with the consideration proposed by 
Hargadon and Sutton (1997) for IDEO case study; the authors find that initially the firm assumes a 
network position able to bridge diverse information and afterwards inbounds the knowledge coming 
from these diverse information. Our results strengthen this case study analysis also within the same 
industrial context. Thus, besides the context issue, raised by Ahuja (2000) to explain why in a 
network of competitors structural holes positions are associated with negative performance (patents) 
while in a network of complementors are associated with a positive performance (new products) 
(Hargadon and Sutton, 1997), we highlight here another important issue: how the firm uses the 
information asset provided by its network position. The open innovation flow concept is a measure 
of how the firm uses its network information; that is to create an incoming flow of knowledge or an 
outgoing one. Here we show that the association between network position, i.e. the information the 
firm has, and the OI_Flow, i.e. how it uses such information, does have an impact on product 
development.  
Our study has important theoretical and managerial implications. Firstly, our results are robust 
and confirmed through two different operationalization of new product development. Secondly, we 
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bridge a gap between SC and OI literatures. SC scholars have pointed out the importance of the 
information asset provided by the structural embeddedness for the firm‟s innovation performance 
(e.g. Ahuja, 2000; Schilling and Phelps, 2007; Perez-Luño et al., 2011). OI scholars have shown 
how the knowledge flow, due to inbound practices, positively impacts on innovation performance 
(e.g. Fey and Birkinshaw, 2005; Vega-Jurado et al., 2009; Un et al., 2010). Both SC and OI 
literatures advantage significantly from this study; indeed, we propose a combination of the 
information asset, provided by network embeddedness, and how the firm uses the information 
available on its network in term of inflowing or outflowing of knowledge, a main focus of OI 
scholars. We show how the two things are related: firm‟s innovation performance, as new product 
development, depends on the interaction between the information assets provided by the network 
position and the use of such asset measured through the open innovation flow. 
Our results significantly impact in terms of managerial perspectives, firstly in the bio-
pharmaceutical context, but also in other industries. Indeed, several studies have signaled to 
managers the strategic importance of product development in bio-pharmaceutical context as a mean 
for acquiring monopoly positions and reduce the "functional incompleteness" of biotech companies 
(Pisano, 1990; Kalaignanam et al., 2007). Furthermore, other studies evidenced how alliances and 
OI practices can improve the ability of the firm to develop new products (Deeds and Hill, 1996; 
Rothaermel and Deeds, 2004). Our findings suggest further directions to bio-pharmaceutical 
managers for improving new product development. Firstly, network positions matter, especially 
centrality (both direct and indirect); indeed, while building a direct central position takes time, since 
the firm has to sign several inter-firm relationships, having an high eigenvector centrality is 
relatively easier since the firm needs to sign an agreement with a highly centrally located firm in the 
network. This, according to our results, seems to put the firm in a position of improving its product 
development performance. Secondly, managers can take advantage by combining structural 
network embeddedness and open innovation flow. According to what evidenced in Figures 5a and 
5c, a firm wishing to improve its product development rate should build, year by year, its central 
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position in the network and exploit it by using inbound practices. On the other hand, if a firm 
wishes to improve its financial performance by selling intermediate innovation products (patents, 
technologies, services) it should exploit its centrality through outbound practices; of course, this 
will reduce the probability to develop new products. Thirdly, while our study provides a neutral 
expectation from gaining structural holes position in a network of inter-firm ties, at least with 
regard to product development processes, we signal how inbound practices seem to activate the 
potentiality gained from the different information that a structural holes position provides. 
5.1 Limitations and further research 
The results and the contributions of this study should be considered in light of its limitations. 
Firstly, this study focuses on the bio-pharmaceutical industry (traditionally involved in innovation 
processes) and excludes other types of industries. Although this approach is appropriate, it would be 
unwise to generalize the findings too broadly to other industries and cultural contexts. Secondly, 
since the analysis is built upon cross-sectional data, the long-term effects could not be investigated. 
The gathering of longitudinal data in which time lags between variables are present would be an 
important step for further investigations. Moroever, as the measure of open innovation (OI_Flow) 
has been newly developed for this study, it requires further validation in future researches. In 
addition, researchers often capture innovation performance with both new developed products and 
number of patents (or other innovation outcomes). We used only new developed products. Thus, not 
only the performance results can be somewhat biased, but also the interpretation of them can be 
different in cases where other innovation measures are employed. Finally, in this study, we start this 
debate by addressing only one dimension of the social capital, i.e. the structural embeddedness, and 
therefore neglecting the relational embeddedness, that has been widely proved to influence firm‟s 
performance (Gulati, 1995; Soh, 2003). Furthermore, Uzzi (1997) developed the notion of 
“overembeddedness” suggesting that inter-firm networks composed mostly of strong ties may 
threaten innovation, rather than enhance it; this theory has obtained some empirical support both in 
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OI (Laursen and Salter, 2006) and SC (Phelps, 2010; Vanhaverbeke et al., 2012) literatures. Here 
we have neglected the impact of “overembeddedness” on the interaction between network positions 
and open innovation flow. Future research might take these considerations into account. 
Acknowledgements 
Authors are gratefully to the anonymous referees of this paper because their suggestions highly 
contribute to the value of the research here presented. 
REFERENCES 
Acquaah, M. (2007). Managerial social capital, strategic orientation, and organizational 
performance in an emerging economy. Strategic Management Journal, 28 (12), 1235- 1255. 
Ahuja, G. 2000. Collaboration networks, structural holes, and innovation: A longitudinal study. 
Administrative Science Quarterly 45 (3): 425–455. 
Bae, J., and M. Gargiulo. 2004. Partner substitutability, alliance network structure, and firm 
profitability in the telecommunications industry. Academy of Management Journal 47 (6): 
843–59. 
Baum, J., Calabrese, T., Silverman, B.S., 2000. Don‟t go it alone: alliance networks and startups‟ 
performance in Canadian biotechnology. Strategic Management Journal, 21, 267–294. 
Belderbos, R., Cassiman, B., Faems, D., Leten, B., and Van Looy, B. 2014. Co-ownership of 
intellectual property: Exploring the value-appropriation and value-creation implications of co-
patenting with different partners. Research Policy, 43(5), 841-852. 
Bianchi, M., A. Cavaliere, D. Chiaroni, F. Frattini, and V. Chiesa. 2011. Organisational modes for 
Open Innovation in the bio-pharmaceutical industry: An exploratory analysis. Technovation 
31 (1): 22-33. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
35 
Bianchi, M., Frattini, F., Lejarraga, J., and Di Minin, A. 2014. Technology Exploitation Paths: 
Combining Technological and Complementary Resources in New Product Development and 
Licensing. Journal of Product Innovation Management, DOI: 10.1111/jpim.12198 
Billiteri, C., G. Lo Nigro, and G. Perrone. 2013. How risk influences the choice of governance 
mode in biopharmaceutical inter-firm relationships. International Business Review 
Borgatti, S. P., M. G. Everett, and L. C. Freeman. 2002. Ucinet 6 for Windows. Harvard, MA: 
Analytic Technologies. 
Burcharth, A. L. D. A., Knudsen, M. P., and Søndergaard, H. A. 2014. Neither invented nor shared 
here: The impact and management of attitudes for the adoption of open innovation practices. 
Technovation, 34(3), 149-161. 
Burt, R. S. 1992. Structural holes: The social structure of competition. Cambridge, MA: Harvard 
University Press. 
Chesbrough, H. 2003. Open Innovation: The New Imperative for Creating and Profiting From 
Technology. Boston, MA: Harvard Business School Press. 
Chiaroni, D., V. Chiesa, and F. Frattini. 2010. Unraveling the process from closed to open 
innovation: Evidence from mature, asset-intensive industries. R&D Management 40 (3): 222–
245. 
Cohen, W.M., and  D. A. Levinthal. 1990. Absorptive capacity: a new perspective on learning and 
innovation. Administrative Science Quarterly 35: 128–152. 
Coleman, J. S. 1988 Social capital in the creation of human capital. American Journal of Sociology 
94: Special Issue, 95–120. 
Dahlander, L. and D. M. Gann. 2010. How open is innovation?. Research Policy 39 (6): 699-709. 
Dahlander, L., and Piezunka, H. 2014. Open to suggestions: How organizations elicit suggestions 
through proactive and reactive attention. Research Policy, 43(5), 812-827. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
36 
Dalal, D. K., & Zickar, M. J. (2012). Some common myths about centering predictors in moderated 
multiple regression and polynomial regression. Organizational Research Methods, 15, 339-
362. 
DeCarolis, D. M., and D. L. Deeds. 1999. The impact of stocks and flows of organizational 
knowledge on firm performance: an empirical investigation of the biotechnology industry. 
Strategic Management Journal 20 (10): 953–968. 
Deeds, D. L., and C. W. L. Hill. 1996. An examination of opportunistic action within research 
alliances: Evidence from the biotechnology industry. Journal of Business Venturing, 14 (2): 
141–63. 
DiMasi, J. A. and Grabowski, H. G. The cost of biopharmaceutical R&D: Is biotech different? 
Management Decision Economics, 28: 469–479. 
Dittrich, K., and G. Duysters. 2007. Networking as a Means to Strategy Change: The Case of Open 
Innovation in Mobile Telephony. Journal of Product Innovation Management 24: 510–521. 
Fey, C., and J. Birkinshaw. 2005. External sources of knowledge, governance mode and R&D 
performance. Journal of Management 31 (4): 597–621. 
Galunic, D.C. and Rodan, S. (1998). Resource recombinations in the firm: knowledge structures 
and the potential for Schumpeterian innovation. Strategic Management Journal, 19, 1193–
1201. 
Geum, Y., S. Lee, B. Yoon, and Y. Park. 2013. Identifying and evaluating strategic partners for 
collaborative R&D: Index-based approach using patents and publications. Technovation 33 
(6–7): 211-224. 
Gilsing, V. A., and B. Nooteboom. 2005. Density and strength of ties in innovation networks: an 
analysis of multimedia and biotechnology. European Management Review 2: 179–97. 
Gilsing, V. A., B. Nooteboom, W. Vanhaverbeke, G. M. Duysters, and A. P. van den Oord. 2008. 
Network embeddedness and the exploration of novel technologies: Technological distance, 
betweenness centrality and density. Research Policy 37 (10): 1717–31. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
37 
Gnyawali, D. R., R. and Madhavan. 2001. Cooperative networks and competitive dynamics: a 
structural embeddedness perspective. Academy of Management Review 26: 431–445. 
Goerzen, A. 2007. Alliance networks and firm performance: The impact of repeated partnerships. 
Strategic Management Journal, 28(5), 487–509. 
Granovetter, M. 1992. Problems of explanation in economic sociology. In Networks and 
Organizations: Structure, Form and Action, Nohria N, Eccles R (eds). Harvard Business 
School Press: Boston, MA; 25–56. 
Gujarati, D. N. 1995. Basic Econometrics. 3rd ed. McGraw-Hill Inc. New York.
Gulati, R. 1995. Social structure and alliance formation patterns: a longitudinal analysis. 
Administrative Science Quarterly 40: 619–52. 
Hargadon, A., and R. I. Sutton. 1997. Technology brokering and innovation in a product 
development firm. Administrative Science Quarterly 42 (4): 716–749. 
He, Y., K.-K. Lai, H. Sun, Y. Chen. 2014. The impact of supplier integration on customer 
integration and new product performance: The mediating role of manufacturing flexibility 
under trust theory. Int. J. Production Economics 147: 260–270. 
Hoetker, G. 2007. The use of logit and probit models in strategic management research: Critical 
issues. Strategic Management Journal 28: 331–343. 
Kalaignanam, K., Shankar, V., Varadarajan, R., 2007. Asymmetric new product development 
alliances: win–win or win–lose partnerships? Management Science 53 (3), 357–374. 
Kale, P., and H. Singh. 2007. Building firm capabilities through learning: the role of the alliance 
learning process in alliance capability and firm-level alliance success. Strategic Management 
Journal, 28 (10): 981–1000. 
Koka, B. R., and J. E. Prescott. 2002. Strategic alliances as social capital: A multidimensional view. 
Strategic Management Journal 23 (9): 795–816. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
38 
Koka, B. R., and J. E. Prescott. 2008. Designing Alliance Networks: The influence of network 
position, environmental change, and strategy on firm performance. Strategic Management 
Journal 29 (6): 639–661. 
Karamanos, A. G. 2012. Leveraging micro‐and macro‐structures of embeddedness in alliance 
networks for exploratory innovation in biotechnology. R&D Management, 42(1), 71-89. 
Koput, K., and Powell, W.W., 2003. Organizational Growth and Alliance Capability: Science and 
Strategy in a Knowledge-Intensive Industry.” Working paper. College of Business and Public 
Administration, University of Arizona. 
Kutvonen, A. 2011. Strategic application of outbound open innovation. European Journal of 
Innovation Management 14 (4): 460-474. 
Laursen, K. and A. Salter. 2006. Open for innovation: The role of openness in explaining 
innovation performance among UK manufacturing firms. Strategic Management Journal, 
27(2): 131–150. 
Lee, D. and Madhavan, R. 2010. Divestiture and Firm Performance: A Meta-Analysis. Journal of 
Management, Vol. 36 (6): 345-1371. 
Li, H. L., and M. J. Tang. 2010. Vertical integration and innovative performance: The effects of 
external knowledge sourcing modes. Technovation 30 (7/8): 401-410. 
Lichtenthaler, U. 2009. Outbound open innovation and its effect on firm performance: Examining 
environmental influences. R&D Management 39 (4): 317–330. 
Lieberman M.B., Montgomery D.B. 1988. First-mover advantages. Strategic Management Journal, 
Summer Special Issue 9: 41–58. 
Little, T. D., J. A. Bovaird, and K. F. Widaman. 2006. On the merits of orthogonalizing powered 
and product terms: Implications for modeling interactions among latent variables. Structural 
Equation Modeling 13: 497-519. 
Long, J. S. 1997. Regression models for categorical and limited dependent variables. Advanced 
Quantitative Techniques in the Social Sciences
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
39 
Malik, T. 2012. Disparate association between alliance social capital and the global pharmaceutical 
firm's performance. International Business Review, 21(6), 1017-1028. 
Maurer, I., and Ebers, M. 2006. Dynamics of social capital and their performance implications: 
Lessons from biotechnology start-ups. Administrative Science Quarterly, 51: 262–292. 
Mazzola, E., and G. Perrone. 2013. A strategic needs perspective on operations outsourcing and 
other inter-firm relationships, Int. J. of Production Economics 144 (1): 256-267. 
Mazzola, E., M. Bruccoleri, and G. Perrone. 2012. The effect of inbound, outbound and coupled 
innovation on performance. International Journal of Innovation Management 16 (6): 
1240008. 
Mina, A., Bascavusoglu-Moreau, E., and Hughes, A. (2014). Open service innovation and the firm's 
search for external knowledge. Research Policy, 43(5), 853-866. 
Molina Morales, Francesc Xavier, and María Teresa Martínez Fernández. 2010. Social networks: 
effects of social capital on firm innovation. Journal of Small Business Management 48 (2): 
258-279
Moran, P., 2005. Structural versus relational embeddedness: social capital and managerial 
performance. Strategic Management Journal 26: 1129–1151. 
Nahapiet, J., and S. Ghoshal. 1998. Social capital, intellectual capital, and the organizational 
advantage. Academy of Management Review 23: 242–266. 
Norton, E., Wang, H., and Ai, C. 2004. Computing Interaction Effects and Standard Errors in Logit 
and Probit Models. STATA Journal 4: 103–116. 
Padula, G. 2008. Enhancing the innovation performance of firms by balancing cohesiveness and 
bridging ties. Long Range Planning 41 (4): 395–411. 
Pèrez-Luño, A., C. Cabello Medina, A. Carmona Lavado, and G. Cuevas Rodrìguez. 2011. How 
social capital and knowledge affect innovation. Journal of Business Research 64 (12): 1369–
1376. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
40 
Phelps, C. 2010. A longitudinal study of the influence of alliance network structure and 
composition on firm exploratory innovation. Academy of Management Journal 53 (4): 890–
913. 
Pieters, M., Hagedoorn, J., Vanhaverbeke, W., & Van de Vrande, V. (2009). The impact of network 
position within the clique. In 2009 Summer Conference, CBS-Copenhagen Business School, 
Denmark. 
Pisano G. 1990. The R&D boundaries of the firm: an empirical analysis. Administrative Science 
Quarterly 35 (1): 153–176. 
Ragatz. G. L.,  R. B. Handfield, and K. J Petersen, 2003. Benefits associated with supplier 
integration into new product development under conditions of technology uncertainty. 
Journal of Business Research, Volume 55(5): 389-400. 
Rothaermel, F. T. 2001. Complementary assets, strategic alliances, and the incumbent‟s advantage: 
an empirical study of industry and firm effects in the biopharmaceutical industry. Research 
Policy 30: 1235–51. 
Rothaermel, F. T., and D. L. Deeds. 2004. Exploration and exploitation alliances in biotechnology: 
a system of new product development. Strategic Management Journal 25 (3): 201–221. 
Salman, N., and  A. L. Saives. 2005. Indirect networks: An intangible resource for biotechnology 
innovation. R&D Management 35 (2): 203– 15. 
Sampson, R. 2007. R&D Alliances and firm performance: the impact of technological diversity and 
alliance organization on innovation. Academy of Management Journal 50 (2): 364–386. 
Schilling, M., and C. Phelps. 2007. Interfirm collaboration networks and knowledge creation: the 
impact of large scale network structure on firm innovation. Management Science 53 (7): 
1113–1126. 
Shipilov, A. V. 2006. Network strategies and performance of Canadian investment banks. Academy 
of Management Journal 49 (3): 590–604. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
41 
Shipilov, A. V., and S. Li. 2008. Can you have your cake and eat it too? Structural holes' influence 
on status accumulation and market performance in collaborative networks. Administrative 
Science Quarterly 58 (1): 73-108. 
Soh, P.-H. 2003. The role of networking alliances in information acquisition and its implication for 
new product performance. Journal of Business Venturing 18: 727–744. 
Stevens, J. 1992. Applied Multivariate Statistics for the Social Sciences. Hillsdale, NJ: Lawrence 
Erlbaum Associates. 
Tomlinson, P.R., F. M. Fai. 2013. The nature of SME co-operation and innovation: A multi-scalar 
and multi-dimensional analysis. Int. J. Production Economics, 141: 316–326. 
Tsai, K. H. 2009. Collaborative networks and product innovation performance: toward a 
contingency perspective. Research Policy 38 (5): 765–778. 
Un, C. A., A. C. Cazurra, and K. Asakawa. 2010. R&D Collaborations and Product Innovation. 
Journal of Product Innovation Management 27 (5): 673–689. 
Uzzi, B. 1996. The sources and consequences of embeddedness for the economic performance of 
organizations: the network effect. American Sociological Review 61: 674–698. 
Vanhaverbeke, W., G. Duysters, and N. Noorderhaven. 2002. External technology sourcing through 
alliances or acquisitions: an analysis of the application-specific integrated circuits industry. 
Organization Science 13 (6): 714–733. 
Vanhaverbeke, W., V Gilsing, B. Beerkens, and G. Duysters. 2009. The role of alliance network 
redundancy in the creation of core and non-core technologies: a local action approach. 
Journal of Management Studies 46 (2): 215-244. 
Vanhaverbeke, W., V. Gilsing, and G. Duysters. 2012. Competence and Governance in Strategic 
Collaboration: The Differential Effect of Network Structure on the Creation of Core and 
Noncore Technology. Journal of Product Innovation Management 29 (5): 784–802. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
42 
Vega-Jurado, J., A. Gutierrez-Gracia, and I. Fernandez-de-Lucio. 2009. Does external knowledge 
sourcing matter for innovation? Evidence from the Spanish manufacturing industry. Industrial 
and Corporate Change 18 (4): 637-670. 
West, J., and Bogers, M. 2013. Leveraging external sources of innovation: a review of research on 
open innovation. Journal of Product Innovation Management. DOI: 10.1111/jpim.12125 
West, J., Salter, A., Vanhaverbeke, W., and Chesbrough, H. 2014. Open innovation: The next 
decade. Research Policy, 43(5), 805-811. 
Wu, W.-P. (2008). Dimensions of social capital and firm competitiveness improvement: The 
mediating role of information sharing. Journal of Management Studies, 45(1), 122–146. 
Zaheer, A., and G. G. Bell. 2005. Benefiting from network position: firm capabilities, structural 
holes, and performance. Strategic Management Journal 26 (9): 809 – 825. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
43 
NewBioProd_d - Probit model NewBioProd_c - Binomial model 
Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 Model 7 Model 8 
Patent Stock -.00028 -.00042* -.00057* -.00045† .2.51e-06 -.00049* -.00070* -.00058* 
(.00021) (.00021) (.00022) (.00021) (.00025) (.000254) (.00028) (.00025) 
R&D Expenditures .325*** .317*** .339*** .313*** .4823*** .4905*** .5183*** .4838*** 
(.0549) (.0532) (.0534) (.0529) (.0992) (.0869) (.0841) (.0874) 
Pipeline .01123 .00926 .00637 .00819 .0392** .0303* .0255† .0277* 
(.0073) (.0072) (.0074) (.0075) (.0783) (.0157) (.01617) (.0166) 
Industry .354* .497** .470* .485** .3014 .6036* .5521* .5408* 
(.170) (.185) (.186) (.189) (.2566) (.2924) (.2918) (.3017) 
Nationality -.273 -.259 -.244 -.274 -.7627* -.7856* -.7813** -.8311** 
(.187) (.188) (.189) (.191) (.3353) (.3254) (.3230) (.324) 
Eigen .0436* .0491† .0463* .0642* .0075 .0601* 
(.0207) (.0272) (.0206) (.0257) (.0478) (.0231) 
Str_holes .183 .180 .175 .4699 .5854 .3659 
(.255) (.259) (.269) (.4149) (.4334) (.4546) 
OI_Flow -.0225 -.0445 .0380 .0117 
(.0964) (.102) (.1581) (.1834) 
EigenXOI_Flow .222** .2698* 
(.0793) (.376) 
Str_holesXOI_Flow .193* .2699** 
(.0788) (.1378) 
Constant -2.51*** -2.70*** -2.73*** -2.68*** -3.892*** -4.357*** -4.359*** -4.249***
(.233) (.251) (.249) (.250) (.409) (.388) (.382) (.388) 
N 544 544 544 544 544 544 544 544 
Wald χ2 56.69*** 73.32*** 73.34*** 75.49*** 110.78*** 134.26*** 98.45*** 146.78*** 
Log- (psedudo) likelihood  -153.66 -150.30 -145.73 -147.29 -207.29 -202.56 -199.56 -200.23
Likelihood ratio test - 6.054
***
2.002
***
 2.134
**
 
Psudo R2 .1863 .2041 .2283 .2200 
Robust standard errors in parentheses † p < 0.10, * p < 0.05, ** p < 0.01, *** p < 0.001 
Table 3. Results of the empirical analysis 
